This Preclinical Biotech Is Going Clinical This Year – And Goldman Says It’s A Buy
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes…
Zenect Wealth
“The Golden Period Of Biotechnology”: 3 Stocks Poised For Massive Growth
The biotechnology sector’s outperformance amid the pandemic has led some analysts to refer to this time as the “golden period of biotechnology”. When it comes…
This Biotech’s Mission Is To Go Global – And Revolutionize Cancer Treatment
“We have a $5 billion market cap now. The next stage is for us to get to $20 billion,” declares the chief executive of the…
3 Stock Tickers With Triple-Digit Upside Potential
A biopharmaceutical company focused on addressing unmet needs in the fields of severe burns and other hard-to-heal wounds and a second biopharmaceutical company focused on…
This Immuno-Oncology Stock Could Be A Compelling Short-Term Play (Or Long-Term Investment)
The clinical-stage biotech highlighted in today’s article – operating in the hot immuno-oncology sector – has both long-term and short-term bull cases to be made…
It’s A Stock Picker’s Market
“This is a market that favors stock picking over market timing and macro analysis,” advises the author of today’s article, who argues that “The business…
These 2 Biotechs Could Revolutionize Disease Treatment And Prevention – And Bring Big Rewards To Risk-Tolerant Investors
“One method of finding great stocks is to hunt down clinical stage companies with potential new treatment methods for diseases and ailments that affect large…
These 5 Stocks Are Popular With Robinhood Users And Analysts Alike
Of the most popular stocks on the Robinhood trading app, which boast the highest analyst ratings? Today’s article identifies the five most popular Robinhood stocks…
The Recent – And Future – Performance Of The Nasdaq Junior Biotechnology Index Amid The Coronavirus Pandemic
Noting that it launched against “perhaps the most consequential backdrop imaginable for the overall Biotech industry,” today’s article examines the recent performance of the Nasdaq…
A First-In-Kind Universal Influenza Vaccine Could Make This Small Biotech A Strong Buy
“Imagine the market for an influenza vaccine that would not require modifications each year to address annual mutations in the influenza virus, that brings about…